Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States. More Details
Slightly overvalued with imperfect balance sheet.
Share Price & News
How has Tabula Rasa HealthCare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TRHC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: TRHC's weekly volatility (7%) has been stable over the past year.
7 Day Return
US Healthcare Services
1 Year Return
US Healthcare Services
Return vs Industry: TRHC underperformed the US Healthcare Services industry which returned 6.8% over the past year.
Return vs Market: TRHC underperformed the US Market which returned 33% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Tabula Rasa HealthCare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StDon't Ignore The Fact That This Insider Just Sold Some Shares In Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC)
1 month ago | Simply Wall StTabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) Intrinsic Value Is Potentially 84% Above Its Share Price
2 months ago | Simply Wall StIs Tabula Rasa HealthCare (NASDAQ:TRHC) Using Too Much Debt?
Is Tabula Rasa HealthCare undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TRHC ($30.2) is trading below our estimate of fair value ($77.7)
Significantly Below Fair Value: TRHC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: TRHC is unprofitable, so we can't compare its PE Ratio to the US Healthcare Services industry average.
PE vs Market: TRHC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TRHC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TRHC is overvalued based on its PB Ratio (9.3x) compared to the US Healthcare Services industry average (6.3x).
How is Tabula Rasa HealthCare forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TRHC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TRHC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TRHC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TRHC's revenue (15.1% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: TRHC's revenue (15.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TRHC's Return on Equity is forecast to be high in 3 years time
How has Tabula Rasa HealthCare performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TRHC is currently unprofitable.
Growing Profit Margin: TRHC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TRHC is unprofitable, and losses have increased over the past 5 years at a rate of 52.4% per year.
Accelerating Growth: Unable to compare TRHC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TRHC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (32.4%).
Return on Equity
High ROE: TRHC has a negative Return on Equity (-122.45%), as it is currently unprofitable.
How is Tabula Rasa HealthCare's financial position?
Financial Position Analysis
Short Term Liabilities: TRHC's short term assets ($89.8M) exceed its short term liabilities ($65.7M).
Long Term Liabilities: TRHC's short term assets ($89.8M) do not cover its long term liabilities ($362.4M).
Debt to Equity History and Analysis
Debt Level: TRHC's debt to equity ratio (455.4%) is considered high.
Reducing Debt: TRHC's debt to equity ratio has reduced from 1343.3% to 455.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TRHC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TRHC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Tabula Rasa HealthCare current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TRHC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TRHC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TRHC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TRHC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TRHC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Calvin Knowlton (71 yo)
Dr. Calvin H. Knowlton, BSc Pharm, MDiv, Ph D., is a Co-Founder of Tabula Rasa Healthcare, Inc. and has been its Chairman and Chief Executive Officer since June 2014. Dr. Knowlton founded Tabula Rasa Healt...
CEO Compensation Analysis
Compensation vs Market: Calvin's total compensation ($USD4.60M) is above average for companies of similar size in the US market ($USD2.34M).
Compensation vs Earnings: Calvin's compensation has been consistent with company performance over the past year.
Experienced Management: TRHC's management team is seasoned and experienced (6.3 years average tenure).
Experienced Board: TRHC's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TRHC insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8%.
Tabula Rasa HealthCare, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Tabula Rasa HealthCare, Inc.
- Ticker: TRHC
- Exchange: NasdaqGM
- Founded: 2009
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: US$705.606m
- Shares outstanding: 23.36m
- Website: https://www.tabularasahealthcare.com
Number of Employees
- Tabula Rasa HealthCare, Inc.
- 228 Strawbridge Drive
- Suite 100
- New Jersey
- United States
Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States. The company operates through two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx,...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/22 00:22|
|End of Day Share Price||2021/09/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.